CASP3 and melanoma: In GSDME-expressing melanoma, the combination of BRAF inhibitors and MEK inhibitors treatment, FDA-approved therapy for BRAF V600E/K mutant melanoma, activates caspase-3 and triggers GSDME pyroptosis.